[The effect of recombinant human growth hormone on urea and creatinine kinetics and selected dialysis adequacy parameters in children with end-stage renal failure treated with peritoneal dialysis].

Unlabelled: The aim of this work was to assess the effect of recombinant human growth hormone (rhGH) on the kinetics of urea and creatinine and selected indices of dialysis adequacy in children with end-stage renal failure treated with peritoneal dialysis. We studied 24 children on peritoneal dialysis, including 10 children aged 9-15.7 years (mean age 12.

Growth hormone therapy and lipid profile in children on chronic peritoneal dialysis.

The aim of the study was to assess the effect of recombinant human growth hormone (rhGH) on serum lipids in children treated with chronic peritoneal dialysis. We studied 26 patients aged 5-18 years, including 13 patients treated with rhGH at a dose of 1-1.1 IU/kg per week for 6 months and a control group of 13 patients.

[Results of treatment with recombinant human growth hormone in children with growth retardation in end-stage renal disease].

The aim of the study was to estimate the results of recombinant human growth hormone (rhGH) treatment in children with end-stage renal disease (ESRD). 60 growth retarded children with ESRD (mean age 11.2 +/- 7.

[Clinical and metabolic effects of erythropoietin administration in hemodialyzed children].

The study aimed at the evaluation of metabolic effect of recombinant human erythropoietin (EPO) in children treated with repeated hemodialyses. The research included 16 patients aged 7-17 years of life. The observations were carried out for 6 months prior to and during EPO administration programme.